You are here: Home » Current Affairs » News » National
Business Standard

DMA takes exception to IMA criticism of Harsh Vardhan over Coronil event

The Delhi Medical Association on Tuesday took exception to the critical statement issued by the IMA on the launch of Patanjali's Coronil tablet in the presence of Union minister Harsh Vardhan

Topics
Harsh Vardhan | Patanjali | indian medical association

Press Trust of India  |  New Delhi 

Harsh Vardhan
Union Minister for Health Harsh Vardhan

The Delhi Medical Association on Tuesday took exception to the critical statement issued by the IMA on the launch of Patanjali's Coronil tablet in the presence of Union minister

The (IMA) on Monday had expressed shock over the "blatant lie of WHO certification" for Patanjali's Coronil tablet, which the company claims is an evidence-based medicine to fight COVID-19, and demanded an explanation from Union Health Minister Vardhan in whose presence the medicine was launched.

In a statement issued on Monday, the IMA said, "Being Health Minister of the country, how justified is it to release such falsely fabricated unscientific product to people of the whole country...can you clarify the time frame, time line for the so-called clinical trial of this said anti-corona product?"

"The country needs an explanation from the minister. The will also write to Medical Commission for seeking suo moto explanation for his blatant disrespect to the code of conduct of Medical Council of India," the IMA had said.

The DMA on Tuesday issued a statement over the IMA statement, saying it "strongly condemns the press release by the Indian Medical Association".

"The content of the press release are baseless, unauthorised, illegal and defamatory for the clean and honest image of Union Minister of Health Dr Harsh Vardhan," it claimed.

Theminister attended the inaugural programme in "his capacity as a union health minister and not as a modern medicine practitioner," it further claimed.

The questions being raised by IMA regarding the nature of trial of CORONIL or on false claims of WHO certification, are to be answered by the research Institute, the DMA said.

In a statement, had earlier said: "Coronil has received the Certificate of Pharmaceutical Product (CoPP) from the Ayush section of Central Drugs Standard Control Organisation as per the WHO certification scheme."


However, WHO South-East Asia in a tweet later said: "@WHO has not reviewed or certified the effectiveness of any traditional medicine for the treatment #COVID19."

had introduced ayurveda-based Coronil on June 23 last year, when the pandemic was at its peak. It had to face severe criticism as it lacked scientific evidence regarding its efficacy.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, February 24 2021. 02:30 IST
RECOMMENDED FOR YOU
.